Introduction

The cytotoxics market is mature and characterized by an increasing level of genericization. Several blockbuster products will undergo patent expiry during the forecast period, however, by virtue of these drugs' success, generic entry will ensure continued growth. Coupled with the launch of several new brands, steady growth of the cytotoxics market will occur to 2018, at a CAGR of 3.1%.

Reasons to Purchase

• Quantify the performance of each of the marketed cytotoxic therapy cancer brands in the seven major markets over the period 2008 to 2018
• Acquire a detailed account of cytotoxic therapy cancer brand dynamics and the events that drive and limit their market growth
• Benchmark the cytotoxic therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot